Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

798.58
+4.390.55%
Volume:236.04K
Turnover:187.41M
Market Cap:82.22B
PE:19.75
High:799.51
Open:782.44
Low:779.08
Close:794.19
52wk High:847.00
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:0.41
T/O Rate:0.24%
Dividend:3.64
Dividend Rate:0.46%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.59
PE(LYR):19.25

Loading ...

Market Chatter: Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program

MT Newswires Live
·
Jun 30

Lilly, Regeneron Selected for US Program to Review New Manufacturing Plants Faster

Reuters
·
Jun 30

Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says

TIPRANKS
·
Jun 30

Eli Lilly, Regeneron Among First Companies Selected for FDA Initiative to Speed Review of New Manufacturing Facilities - CNBC

THOMSON REUTERS
·
Jun 30

Healthcare Stocks Have Become a Haven for Investors Ditching Tech

Dow Jones
·
Jun 27

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jun 27

How Investors May Respond To Regeneron Pharmaceuticals (REGN) Cemdisiran Priority Review for gMG Treatment

Simply Wall St.
·
Jun 27

Regeneron Updates Financial Calendar for Second-quarter Results Release and Conference Call

Reuters
·
Jun 26

Regeneron’s New First-in-Human Eczema Drug REGN20423: Early Trial Progress and Investor Takeaways

TIPRANKS
·
Jun 26

Kymera Rises on Accelerated Trial Timeline for Experimental Eczema Drug

Reuters
·
Jun 25

AbbVie is buying a biotech working on an experimental eczema drug for $10.9 billion

Dow Jones
·
Jun 22

Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis

Dow Jones
·
Jun 22

Regeneron says FDA accepts cemdisiran gMG filing for priority review

Reuters
·
Jun 22

Regeneron Pharmaceuticals - FDA to Review Cemdisiran Nda Under Priority Review With Target Action Date November 2026

THOMSON REUTERS
·
Jun 22

Regeneron Pharmaceuticals - European Commission Decision on Cemdisiran Expected in Second Half of 2027

THOMSON REUTERS
·
Jun 22

Cemdisiran Regulatory Submissions Accepted for Review by FDA and Ema for the Treatment of Generalized Myasthenia Gravis (Gmg)

THOMSON REUTERS
·
Jun 22

Regeneron Pharmaceuticals - Plans Regulatory Filing for Cemdisiran in Japan in Early 2027

THOMSON REUTERS
·
Jun 22

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

GlobeNewswire
·
Jun 22

AbbVie would gain an experimental eczema drug by buying biotech: report

Dow Jones
·
Jun 21

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Jun 18